Disease-modifying therapies in relapsing–remitting multiple sclerosis

References

• LucchinettiCBrückWParisiJScheithauerBRodriguezMLassmannHHeterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelinationAnn Neurol20004770771710852536
   PubMed Web of Science ®Google Scholar
• KasperLHShoemakerJMultiple sclerosis immunology. The healthy immune system vs the MS immune systemNeurology201074Suppl 1S2S820038759
   PubMed Web of Science ®Google Scholar
• PolmanCReingoldSEdanGDiagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the “McDonald Criteria”Ann Neurol20055884084616283615
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRSimonJIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study GroupN Engl J Med20003431389890411006365
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple SclerosisAnn Neurol20015012112711456302
   PubMed Web of Science ®Google Scholar
• McDonaldWIRelapse, remission, and progression in multiple sclerosisN Engl J Med2000343201486148711078776
   PubMed Web of Science ®Google Scholar
• CohenJACalabresiPAChakrabortySAvonex combination trial in relapsing–remitting MS: Rationale, design and baseline dataMult Scler20081437038218208877
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• World Health Organization and Multiple Sclerosis International FederationAtlas: Multiple Sclerosis Resources in the WorldGenevaWorld Health Organization Press2008
   Google Scholar
• PugliattiMRosatiGCartonHThe epidemiology of multiple sclerosis in EuropeEur J Neurol200613770072216834700
   PubMed Web of Science ®Google Scholar
• WilliamsonDMNoonanCWHenryJPThe prevalence of multiple sclerosis in 3 US communitiesPrev Chronic Dis201071A1220040227
   PubMed Web of Science ®Google Scholar
• MayrWTPittockSJMcClellandRLJorgensenNWNoseworthyJHRodriguezMIncidence and prevalence of multiple sclerosis in Olmsted County, Minnesota 1985–2000Neurology200361101373137714638958
   PubMed Web of Science ®Google Scholar
• GoldbergLDEdwardsNCFincherCDoanQVAl-SabbaghAMeleticheDMComparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing–remitting multiple sclerosisJ Manag Care Pharm200915754355519739877
   PubMed Web of Science ®Google Scholar
• GuoSBozkayaDWardAO’BrienJAIshakKBennettRTreating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: Modelling the clinical and economic implicationsPharmacoeconomics2009271395319178123
   PubMed Web of Science ®Google Scholar
• RiceGPAIncorvaiaBMunariLMInterferon in relapsing–remitting multiple sclerosisCochrane Database Syst Rev2001CD00200211687131
   PubMedGoogle Scholar
• ClericoMFaggianoFPalaceJRiceGPATintorè SubiranaMDurelliLRecombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosisCochrane Database Syst Rev2008CD00527818425915
   PubMed Web of Science ®Google Scholar
• MunariLMLovatiRBoikoATherapy with glatiramer acetate for multiple sclerosisCochrane Database Syst Rev2003CD004678
   Web of Science ®Google Scholar
• FordCGoodmanAJohnsonKContinuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMult Scler201016334235020106943
   PubMed Web of Science ®Google Scholar
• LindaHvon HeijneAMajorEORyschkewitschCBergJOlssonTMartinCProgressive multifocal leukoencephalopathy after natalizumab monotherapyN Engl J Med2009361111081108719741229
   PubMed Web of Science ®Google Scholar
• JilekSJaquiéryEHirschHHImmune responses to JC virus in patients with multiple sclerosis treated with natalizumab: A cross-sectional and longitudinal studyLancet Neurol20109326427220117055
   PubMed Web of Science ®Google Scholar
• BrownBANatalizumab in the treatment of multiple sclerosisTher Clin Risk Manag2009558559419707275
   PubMedGoogle Scholar
• GrayOMcDonnellGVForbesRBIntravenous immunoglobulins for multiple sclerosisCochrane Database Syst Rev2003CD00293614583956
   PubMed Web of Science ®Google Scholar
• Martinelli BoneschiFRovarisMCapraRComiGMitoxantrone for multiple sclerosisCochrane Database Syst Rev2005CD00212716235298
   PubMed Web of Science ®Google Scholar
• CasettaIIulianoGFilippiniGAzathioprine for multiple sclerosisCochrane Database Syst Rev2007CD00398217943809
   PubMed Web of Science ®Google Scholar
• SolariAUitdehaagBMJGiulianiGPucciETausCAminopyridines for symptomatic treatment in multiple sclerosisCochrane Database Syst Rev2002CD00133012804404
   PubMedGoogle Scholar
• La MantiaLMilaneseCMascoliND’AmicoRWeinstock-GuttmanBCyclophosphamide for multiple sclerosisCochrane Database Syst Rev2007CD00281917253481
   PubMed Web of Science ®Google Scholar
• GrayOMcDonnellGVForbesRBMethotrexate for multiple sclerosisCochrane Database Syst Rev2004CD00320815106195
   PubMed Web of Science ®Google Scholar
• BennettMHHeardRHyperbaric oxygen therapy for multiple sclerosisCochrane Database Syst Rev2004CD00305714974004
   PubMed Web of Science ®Google Scholar
• WynnDKaufmanMMontalbanXDaclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaLancet Neurol20104422107003370038
   Google Scholar
• SorensenPSMellgrenSISvenningssonANORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing–remitting Multiple Sclerosis (NORMIMS study): A randomised, placebo-controlled trialLancet Neurol20098651952919409854
   PubMed Web of Science ®Google Scholar
• ConwayDCohenJACombination therapy in multiple sclerosisLancet Neurol20109329930820170843
   PubMed Web of Science ®Google Scholar
• PattiFAmatoMPBastianelloSEffects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing–remitting multiple sclerosisMult Scler2010161687719995846
   PubMed Web of Science ®Google Scholar
• BermelRAWeinstock-GuttmanBBourdetteDFouldsPYouXRudickRIntramuscular interferon beta-1a therapy in patients with relapsing–remitting multiple sclerosis: A 15-year follow-up studyMult Scler2182010 [Epub ahead of print]
   Web of Science ®Google Scholar
• CohenBARiveraVMPRISMS: The story of a pivotal clinical trial series in multiple sclerosisCurr Med Res Opin201026482783820121658
   PubMed Web of Science ®Google Scholar
• GuoSBozkayaDWardAO’BrienJATreating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: Modelling the clinical and economic implicationsPharmacoeconomics2009271395319178123
   PubMed Web of Science ®Google Scholar
• GauthierSAGlanzBIMandelMIncidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort studyJ Neurol Sci20092841211611919380153
   PubMed Web of Science ®Google Scholar
• CohenBAKhanOJefferyDRIdentifying and treating patients with suboptimal responsesNeurology20046312 Suppl 6S33S4015623669
   PubMed Web of Science ®Google Scholar
• SorensenPSDeisenhammerFDudaPGuidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-β antibodies in multiple sclerosisEur J Neurol2005121181782716241970
   PubMed Web of Science ®Google Scholar
• JohnsonKPRisks vs benefits of glatiramer acetate: A changing perspective as new therapies emerge for multiple sclerosisTher Clin Risk Manag2010615317220421914
   PubMed Web of Science ®Google Scholar
• RudickRAPolmanCHCurrent approaches to the identification and management of breakthrough disease in patients with multiple sclerosisLancet Neurol20098654555919446274
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosisAnn Neurol20015012112711456302
   PubMed Web of Science ®Google Scholar
• PelayoRMontalbanXMinovesTDo multimodal evoked potentials add information to MRI in clinically isolated syndromes?Mult Scler2010161556119995838
   PubMed Web of Science ®Google Scholar
• LuqueFAJaffeSLCerebrospinal fluid analysis in multiple sclerosisInt Rev Neurobiol2007793415617531849
   PubMed Web of Science ®Google Scholar
• SchapiroRTThe symptomatic management of multiple sclerosisAnn Indian Acad Neurol200912429129520182577
   PubMed Web of Science ®Google Scholar
• CalabresiPADiagnosis and management of multiple sclerosisAm Fam Physician200470101935194415571060
   PubMed Web of Science ®Google Scholar
• BertolottoAMalucchiSSalaADifferential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: A follow up study in an independent laboratoryJ Neurol Neurosurg Psychiatry200273214815312122172
   PubMed Web of Science ®Google Scholar
• KinkelRPKollmanCO’ConnorPIM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating eventNeurology200666567868416436649
   PubMed Web of Science ®Google Scholar
• PRISMS Study groupRandomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• SchwidSRPanitchHSFull results of the Evidence of Interferon Dose- Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosisClin Ther20072992031204818035202
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPIndependent Comparison of Interferon (INCOMIN) Trial Study GroupEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2 year prospective randomized multicenter study (INCOMIN)Lancet20023591453146011988242
   PubMed Web of Science ®Google Scholar
• Koch-HenriksenNSørensenPSChristensenTDanish Multiple Sclerosis GroupA randomized study of two interferon-beta treatments in relapsing–remitting multiple sclerosisNeurology20066671056106016510769
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomized, parallel, open-label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMBarkhofFETOMS study groupEffect of early interferon treatment on conversion to definite multiple sclerosis; a randomised study: The ETOMS trialLancet20013571576158211377645
   PubMed Web of Science ®Google Scholar
• CohenJAImreyPBCalabresiPAEdwardsKREickenhorstTFeltonWL3rdResults of the Avonex Combination Trial (ACT) in relapsing– remitting MSNeurology200972653554119204263
   PubMed Web of Science ®Google Scholar